Berry Genomics Co (000710.SZ) Aktie Kurs

Berry Genomics Co., Ltd. generates revenue through basic scientific research services, medical testing services, and the sale of reagents and equipment. The company provides transcriptome sequencing, human whole exome sequencing, and whole genome sequencing for scientific research clients. Medical testing services include tumor genetic testing, genetic disease testing, and reproductive health testing for healthcare providers. Reagent and equipment sales feature the NextSeq CN500 gene sequencer and general reagents for sequencing reactions, targeting research institutions and medical facilities. The primary buyers of basic scientific research services are research institutions requiring advanced sequencing platforms. Medical testing services are purchased by healthcare providers offering diagnostic solutions. Reagent and equipment sales target both research and medical sectors, with the NextSeq CN500 gene sequencer being a key product for high-throughput sequencing needs. The company's revenue streams are segmented by service type, with research services and medical testing forming the core business segments. Berry Genomics' product portfolio includes sequencing platforms, testing reagents, and equipment like the NextSeq CN500 gene sequencer. These products serve research institutions and medical facilities, with medical testing services focusing on tumor, genetic disease, and reproductive health applications. The company's sales strategy emphasizes high-throughput sequencing technology solutions for both scientific and medical markets.